SCHEMBL162239

SCHEMBL162239

CCCNC(=O)c1conc1[O]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.47
MAOB P27338 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
THRB P10828 1/20 0.43
RECQL P46063 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TSHR P16473 2/20 0.41
HTT P42858 1/20 0.41
TP53 P04637 3/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
LMNA P02545 2/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
GAA P10253 2/20 0.40
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NAAA Q02083 1/20 0.39
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163915 0.90 TSHR (0.54) L3MBTL1TSHRHTTTP53SMN1; SMN2
SCHEMBL163200 0.86 L3MBTL1 (0.39) L3MBTL1TSHRHPGDLMNAGAA
SCHEMBL163561 0.79 RAB9A (0.44) POLBMAOBTSHRHTTTP53
SCHEMBL163314 0.74 KMT2A (0.50) MAOBL3MBTL1RECQLTSHRHTT
SCHEMBL162580 0.71 HPGD (0.46) POLBMAOBL3MBTL1THRBRECQL
SCHEMBL161102 0.70 POLB (0.43) POLBL3MBTL1THRBRECQLTDP1
SCHEMBL164175 0.69 TSHR (0.38) POLBTSHRALDH1A1HPGDLMNA
SCHEMBL162691 0.69 TSHR (0.51) POLBL3MBTL1THRBRECQLTDP1
SCHEMBL163082 0.69 POLB (0.49) POLBMAOBL3MBTL1THRBRECQL
SCHEMBL22505247 0.69 POLB (0.61) POLBMAOBL3MBTL1THRBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 POLB 690/4885MAOB 1218/4885L3MBTL1 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.